Prolinol, (R)- → 5-(5-{[(3S)-3-hydroxy-1-pyrrolidinyl]methyl}-3-thienyl)-3-{1-[(1-methylethyl)sulfonyl]-4-piperidinyl}-1H-indole-7-carboxamide
반응식
OC[C@H:3]1[CH2:7][CH2:6][CH2:5][N:4]1[CH2:8][C:9]1[S:13][CH:12]=[C:11]([C:14]2[CH:15]=[C:16]3[C:20](=[C:21]([C:23]([NH2:25])=[O:24])[CH:22]=2)[NH:19][CH:18]=[C:17]3[CH:26]2[CH2:31][CH2:30][N:29]([S:32]([CH:35]([CH3:37])[CH3:36])(=[O:34])=[O:33])[CH2:28][CH2:27]2)[CH:10]=1.N1CCC[C@@H]1C[OH:44]>>[OH:44][C@H:6]1[CH2:7][CH2:3][N:4]([CH2:8][C:9]2[S:13][CH:12]=[C:11]([C:14]3[CH:15]=[C:16]4[C:20](=[C:21]([C:23]([NH2:25])=[O:24])[CH:22]=3)[NH:19][CH:18]=[C:17]4[CH:26]3[CH2:27][CH2:28][N:29]([S:32]([CH:35]([CH3:37])[CH3:36])(=[O:34])=[O:33])[CH2:30][CH2:31]3)[CH:10]=2)[CH2:5]1참가 물질
3
반응물 2
생성물 1
실험 절차
The title compound was prepared according to the general procedure of 5-(5-{[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl}-3-thienyl)-3-{1-[(1-methylethyl)sulfonyl]-4-piperidinyl}-1H-indole-7-carboxamide, substituting (3S)-3-pyrrolidinol (90.13 mg, 1.20 mmol) for (2R)-2-pyrrolidinylmethanol to afford 12.8 mg of the title compound (53.1%).